Author Archives: Somi Igbene

ReS3-T Accepted Into Epilepsy Therapy Screening Program

ReS3-T, an investigational medicine developed by reMynd for therapy-resistant epilepsies such as Dravet syndrome, has been accepted into the National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). The ETSP identifies potential therapies for drug-resistant epilepsy and disease prevention and modification by allowing researchers…